Redox Paradox: Oxidative Stress in Lacrimal Gland Protection and Injury

The Dual Role of Reactive Oxygen Species in the Lacrimal Functional Unit

The physiology of the lacrimal functional unit (LFU) relies heavily on a delicate balance of reactive oxygen species (ROS) and antioxidants. At controlled levels, ROS act as signaling molecules that regulate apoptosis, wound healing, transcription factors, and innate immune responses, which are essential for maintaining ocular surface health. When ROS production surpasses the neutralizing capacity of antioxidants, the resulting oxidative stress (OS) leads to molecular damage, cellular dysfunction, and tissue degeneration. The LFU, comprising the ocular surface, lacrimal glands, and neural feedback loops, is particularly sensitive to fluctuations in this redox state. This vulnerability arises from its constant exposure to environmental triggers, including ultraviolet radiation, pollutants, and pathogens.

The protective role of OS stems from its evolutionary embedding in innate immunity. Peroxidases such as lactoperoxidase (LPO) and glutathione peroxidase (GPx) harness ROS to disrupt bacterial membranes, inhibit microbial enzymes, and suppress pathogenic DNA synthesis. These mechanisms provide antimicrobial surveillance at the ocular surface, transforming ROS into a frontline defense element. However, these same enzymatic systems can become maladaptive under conditions of chronic ROS accumulation. Instead of conferring protection, ROS-driven cascades can initiate lipid peroxidation, protein oxidation, and DNA damage that culminate in dry eye disease (DED) and other ocular surface disorders.

This duality generates a paradox in which biomarkers of oxidative activity may signify both health and pathology. For example, increased peroxidase activity may be interpreted either as enhanced defense against microorganisms or as an indicator of excessive oxidative load in degenerating tissues. Distinguishing between these states remains a major challenge in interpreting biochemical assays of tear film and lacrimal gland activity. This ambiguity complicates the development of targeted therapies because interventions that suppress ROS indiscriminately may also compromise essential immune functions. Thus, therapeutic strategies must embrace the complexity of OS as both protective and damaging.

The transition from protective ROS signaling to pathological OS is context-dependent, influenced by hormonal status, metabolic conditions, and environmental exposures. In diabetes, hypothyroidism, and autoimmune disorders such as Sjögren’s syndrome, the antioxidant capacity of the LFU becomes impaired, tipping the balance toward damage. In contrast, calorie restriction or controlled exercise can enhance antioxidant defenses and restore redox equilibrium. This tension between resilience and vulnerability underscores the need for mechanistic insight into ROS dynamics, paving the way toward therapeutic modulation of oxidative states.

Endogenous and Exogenous Sources of Oxidative Stress in Ocular Tissues

The genesis of ROS arises from both endogenous metabolic pathways and exogenous environmental assaults. Mitochondrial electron transport remains the dominant source of physiological ROS, with electrons leaking to molecular oxygen to form superoxide radicals. Additional intracellular sources include cytochrome P450 metabolism, xanthine oxidase activity, NADPH oxidase-driven redox cycling, and nitric oxide synthase uncoupling. Peroxisomes and transition metal-catalyzed oxidation reactions further amplify ROS generation, making every cell in the LFU a potential site of oxidative imbalance. These processes occur continuously under aerobic metabolism, underscoring why ocular tissues—metabolically active and highly vascularized—are particularly prone to ROS fluctuations.

Exogenous sources such as ultraviolet (UV) radiation play a decisive role in ocular oxidative stress. The cornea and conjunctiva are directly exposed to solar radiation, triggering chromophore excitation in flavins, porphyrins, tryptophan, and melanin. These excited states transfer energy to oxygen, generating singlet oxygen and superoxide radicals that propagate photochemical damage. Airborne toxins, cigarette smoke, and industrial pollutants further enrich the oxidative burden by introducing xenobiotics that undergo redox cycling. Pathogens also stimulate ROS as part of host defense, although excessive immune activation can lead to collateral tissue injury. Collectively, these exogenous triggers continuously challenge the antioxidant defenses of the LFU.

The defense against these oxidative challenges relies on a network of antioxidant enzymes. Superoxide dismutase (SOD) dismutates superoxide into hydrogen peroxide, which is subsequently neutralized by catalase and peroxidases. Lactoperoxidase, secreted into tears, functions both as an antimicrobial factor and as a modulator of ROS balance. Glutathione peroxidases detoxify lipid hydroperoxides, preventing membrane damage and preserving acinar cell viability. These enzymes function cooperatively, but their expression levels and activity vary across ocular tissues, making some compartments more vulnerable to oxidative damage than others.

The continuous interplay between endogenous metabolism and exogenous insults positions the LFU at the crossroads of oxidative adaptation. When antioxidant capacity matches ROS load, ocular surface integrity is preserved. When this balance falters, cumulative damage manifests as epithelial apoptosis, glandular dysfunction, and impaired tear film homeostasis. Understanding these dynamic sources of ROS is essential for developing therapies that can selectively modulate redox pathways without undermining physiological signaling. This complexity became evident through decades of historical investigations into ocular peroxidases and their biomarkers.

Historical Investigations into Ocular Peroxidases

Since the mid-twentieth century, researchers have recognized peroxidases as central mediators of oxidative activity in the lacrimal gland and tear film. Early immunological studies detected peroxidase granules in acinar cells, linking their presence to the viability of secretory pathways. Experiments in rodents established that parasympathetic-like stimulation could modulate peroxidase activity, identifying these enzymes as dynamic markers of lacrimal gland function. With aging, however, peroxidase secretion declines, highlighting their potential role in age-related dry eye pathology. These discoveries established peroxidase activity as a biomarker of both physiological function and disease vulnerability.

Lactoperoxidase (LPO) emerged as a prototypical enzyme of interest due to its constitutive secretion in tears, saliva, and other exocrine fluids. Its structural similarity to salivary peroxidase suggested evolutionary conservation, and its antimicrobial properties confirmed its role in innate defense. Enzymatic assays measuring tear peroxidase activity were widely applied as proxies for lacrimal gland bioactivity, but interpretations were often confounded by cross-reactivity and methodological limitations. For decades, it remained unclear whether elevated peroxidase activity reflected protective upregulation or pathological overdrive. This ambiguity contributed to the paradoxical interpretation of oxidative biomarkers.

Other enzymes enriched the redox landscape of ocular tissues. Catalase, although not abundantly secreted into tears, was confirmed in lacrimal gland peroxisomes, where it catalyzes hydrogen peroxide decomposition. Superoxide dismutase was identified in virtually all mammalian cells, with knockout models demonstrating its critical role in preventing lacrimal gland atrophy and accelerated aging. Additional factors, such as peroxiredoxins and erythropoietin, emerged as modulators of redox balance, expanding the catalog of antioxidant systems beyond peroxidases. Together, these enzymes form a multilayered defense network that reflects both redundancy and specialization.

Despite this rich history, the limitations of biochemical assays hindered precise interpretation. Generic terms like “peroxidase activity” masked the contributions of specific isoforms with distinct functions and substrates. This lack of specificity has perpetuated confusion in correlating enzymatic activity with clinical outcomes in dry eye disease. Modern proteomic and immunoassay approaches have begun to refine this landscape, distinguishing isoforms and revealing patterns of dysregulation in disease models. These refinements allow a more nuanced understanding of oxidative dynamics, guiding the transition toward therapeutic interventions.

Biological Evidence of ROS in Lacrimal Gland and Ocular Surface

Experimental models have demonstrated that the lacrimal gland possesses robust antioxidant defenses relative to other tissues. In diabetic rat models, peroxidase activity increased, reflecting an adaptive response to hyperglycemia-induced oxidative burden. However, markers of lipid peroxidation such as malondialdehyde accumulated simultaneously, revealing that enhanced peroxidase activity was insufficient to fully neutralize oxidative damage. These findings underscore the complexity of interpreting enzyme upregulation, as compensatory responses may coexist with pathological outcomes. The dissociation between enzymatic activity and tissue preservation reflects the limitations of using single biomarkers to evaluate oxidative states.

Autoimmune diseases such as Sjögren’s syndrome highlight the interplay between ROS and immune activation. In this context, oxidative stress induces aberrant signaling through pathways like MAPK, leading to overexpression of Ro52/SSA proteins that eventually become autoantigens. The resulting autoantibody production exacerbates inflammation and perpetuates glandular dysfunction. Tear proteomics from patients with Sjögren’s syndrome has revealed elevated levels of antioxidant enzymes alongside increased proinflammatory proteins, illustrating the paradox of simultaneous protection and injury. These findings suggest that oxidative stress does not act in isolation but interacts with immune dysregulation to shape disease outcomes.

Sex hormones also modulate oxidative dynamics within the LFU. Studies have shown that female hamsters exhibit higher lacrimal gland peroxidase activity than males, and that androgens can suppress this activity. These findings raise the possibility that hormonal differences contribute to the higher prevalence of dry eye in women. However, data from rodent and human studies are inconsistent, and cross-reactivity among enzymes complicates interpretation. Nonetheless, the observed sex-specific modulation suggests that redox pathways intersect with endocrine regulation, amplifying the complexity of therapeutic targeting.

The microbiota further adds a systemic dimension to oxidative modulation. Gut dysbiosis alters immune balance, promoting exaggerated inflammation and oxidative stress in the ocular surface. In contrast, diverse microbiota mitigate oxidative damage through metabolite circulation and regulatory T-cell modulation. These findings link systemic ecology to ocular redox balance, suggesting that interventions beyond the eye itself may influence lacrimal gland health. This systemic view of oxidative stress reframes dry eye not merely as a local disease but as an emergent property of multisystem interactions.

Clinical Evidence Linking Oxidative Stress to Dry Eye Disorders

Clinical studies corroborate experimental findings by associating oxidative biomarkers with dry eye severity. Tear proteomic analyses have identified reductions in lactoperoxidase levels in dry eye patients, accompanied by increases in proinflammatory mediators. These biochemical changes align with clinical observations of reduced tear stability and epithelial damage. Biomarkers such as 8-hydroxy-2’-deoxyguanosine and lipid peroxidation products have been detected in tears and conjunctival tissues, correlating with inflammatory cell infiltration and ocular surface impairment. These findings support the role of oxidative stress as both a contributor and marker of disease progression.

In Sjögren’s syndrome, salivary and tear samples exhibit elevated oxidative markers alongside reduced antioxidant enzyme activity. The interplay between systemic autoimmunity and local redox imbalance suggests a dual mechanism in which oxidative stress not only damages tissues but also fuels autoantigen exposure. This dynamic contributes to the chronicity and refractoriness of autoimmune dry eye. Similar patterns are observed in other systemic diseases, including rheumatoid arthritis and systemic sclerosis, where oxidative imbalances intersect with inflammation to exacerbate glandular dysfunction. These clinical associations reinforce the notion that oxidative stress is a central node in multifactorial disease processes.

Age-related dry eye further illustrates the cumulative impact of oxidative imbalance. Older individuals exhibit reduced peroxidase secretion, impaired tear film stability, and accumulation of oxidative byproducts in lacrimal glands. These changes align with structural degeneration, secretory dysfunction, and inflammatory infiltration observed in aged animal models. Calorie restriction and antioxidant supplementation have been shown to mitigate some of these effects, suggesting that lifestyle interventions can influence ocular oxidative balance. These findings position oxidative stress as both a biomarker and a therapeutic target in age-related ocular surface disease.

Despite these associations, clinical evidence remains limited by variability in assay specificity and patient heterogeneity. The same oxidative marker may signify adaptive protection in one context and pathological damage in another. This interpretive ambiguity hinders the clinical utility of oxidative biomarkers for diagnosis and monitoring. The challenge lies in refining assays to distinguish between protective ROS signaling and harmful oxidative overload, thereby guiding therapeutic decisions. These limitations underscore the urgency of advancing therapeutic strategies designed to modulate oxidative balance.

Therapeutic Perspectives: Nutrition, Pharmacology, and Lifestyle

Therapeutic approaches targeting oxidative stress in dry eye encompass dietary interventions, pharmacological agents, and lifestyle modifications. Nutritional strategies emphasize micronutrient supplementation, including vitamins, selenium, and omega-3 fatty acids, which enhance antioxidant defenses. Clinical trials have reported modest improvements in tear stability and ocular surface integrity with such supplements, although methodological limitations temper these findings. Autologous serum eye drops, rich in antioxidant proteins, provide another avenue for replenishing protective factors in the tear film. These interventions highlight the feasibility of bolstering natural defenses through supplementation.

Pharmacological approaches include antioxidant-enriched eye drops and reformulated medications that eliminate pro-oxidant preservatives. For instance, removing benzalkonium chloride from cyclosporine formulations reduces oxidative injury and enhances therapeutic efficacy. Topical agents containing selenium or vitamin B12 have shown potential in improving corneal epithelial health, although long-term benefits remain uncertain. The complexity of redox signaling demands caution, as excessive suppression of ROS may impair antimicrobial defense. Thus, pharmacological interventions must strike a balance between quenching harmful oxidative cascades and preserving physiological ROS signaling.

Lifestyle modifications such as calorie restriction and controlled exercise have demonstrated consistent benefits in experimental models. Calorie restriction reduces mitochondrial ROS generation, preserves lacrimal gland structure, and attenuates inflammatory infiltration. Exercise enhances antioxidant enzyme activity, although excessive exertion may paradoxically increase oxidative load. The relationship between lifestyle factors and ocular oxidative balance remains complex, but available evidence supports the inclusion of behavioral interventions in therapeutic regimens. These strategies reinforce the concept that systemic metabolic health influences ocular surface resilience.

The gut microbiota represents a frontier in therapeutic innovation. Manipulating microbial diversity through probiotics or dietary modifications may indirectly reduce ocular oxidative stress by regulating immune and metabolic pathways. Dysbiosis-induced inflammation and oxidative imbalance in the LFU illustrate the systemic nature of ocular disease. Addressing these systemic contributors expands therapeutic perspectives beyond the ocular surface itself, integrating nutrition, microbiota, and lifestyle into holistic treatment strategies. This integrative approach offers promise but requires rigorous clinical validation to establish efficacy and safety.

Study DOI: https://doi.org/10.3389/fcell.2022.824726

Engr. Dex Marco Tiu Guibelondo, B.Sc. Pharm, R.Ph., B.Sc. CpE

Editor-in-Chief, PharmaFEATURES